Apple Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 20 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.49 M
as on 17-11-2024
- Revenue 8.80%
(FY 2023)
- Profit -17.19%
(FY 2023)
- Ebitda 4.29%
(FY 2023)
- Net Worth 16.60%
(FY 2023)
- Total Assets 2.69%
(FY 2023)
About Apple Therapeutics
The Corporate was formerly known as Protech Therapeutics Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.49 M.
Asheesh Srivastava and Sanjeev Tomar serve as directors at the Company.
- CIN/LLPIN
U24232DL2004PTC127958
- Company No.
127958
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Apple Therapeutics Private Limited offer?
Apple Therapeutics Private Limited offers a wide range of products and services, including Ointment, Mouth Ulcer Gel, Body Care Products, Body Lotions, Hair Shampoo, Anti Dandruff Shampoo, Baby Creams & Lotion, Baby Lotion, Psoriasis Medicine, Face Cream.
Who are the key members and board of directors at Apple Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Asheesh Srivastava  | Director | 04-Aug-2005 | Current |
| Sanjeev Tomar | Director | 21-Nov-2014 | Current |
Financial Performance of Apple Therapeutics.
Apple Therapeutics Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.8% increase. The company also saw a substantial fall in profitability, with a 17.19% decrease in profit. The company's net worth Soared by an impressive increase of 16.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apple Therapeutics?
In 2023, Apple Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Mar 2020 | ₹2.49 M | Open |
How Many Employees Work at Apple Therapeutics?
Apple Therapeutics has a workforce of 142 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apple Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apple Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
